Celltrion Says New Data Prove Remsima SC Is A ‘Biobetter’

Subcutaneous Infliximab Shows Improved Outcomes Compared To Intravenous Version

 
• By Dave Wallace

Celltrion says new data show that its Remsima SC subcutaneous infliximab biosimilar produces “statistically greater improvements in clinical outcomes” for rheumatoid arthritis patients compared to intravenous infliximab.

Better word clouds
Celltrion’s subcutanous infliximab performed better than the intravenous version • Source: Shutterstock

More from Biosimilars

More from Products